🇺🇸 FDA

Intelligence · Clinical Pipeline

TG THERAPEUTICS Pipeline

All ClinicalTrials.gov programs at TG THERAPEUTICS — phase, modality, and trial IDs.

Programs
39

Quick answer

TG THERAPEUTICS has 39 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Fingolimod placebo, FINGOLIMOD, Ublituximab Placebo, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  2. Obinutuzumab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial

  3. Ublituximab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    5 trials

  4. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis (RMS)

    phase 3 mab active

    3 trials

  5. Ublituximab

    TG THERAPEUTICS, INC.

    Diffuse Large B-Cell Lymphoma

    phase 3 mab terminated

    1 trial

  6. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    3 trials

  7. Ublituximab, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing forms of Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  8. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  9. ublituximab, DEXAMETHASONE, PARACETAMOL, GADOBUTROL, ublituximab placebo, DIPHENHYDRAMINE, CETIRIZINE, METHYLPREDNISOLONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial

  10. Acalabrutinib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  11. Pembrolizumab

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 2 mab terminated

    1 trial

  12. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  13. TGR-1202

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  14. Ublituximab

    TG THERAPEUTICS, INC.

    multiple sclerosis

    phase 2 small molecule active

    1 trial

  15. Ublituximab

    TG THERAPEUTICS, INC.

    Non-Hodgkins Lymphoma

    phase 2 small molecule completed

    2 trials

  16. Ublituximab

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  17. Ublituximab

    TG THERAPEUTICS, INC.

    Autoimmune Disorders

    phase 2 small molecule active

    1 trial

  18. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Remitting Multiple Sclerosis

    phase 2 mab completed

    1 trial

  19. Umbralisib

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule completed

    4 trials

  20. Umbralisib

    TG THERAPEUTICS, INC.

    Marginal Zone Lymphoma

    phase 2 small molecule completed

    1 trial

  21. Umbralisib

    TG THERAPEUTICS, INC.

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  22. Venetoclax

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  23. Azercabtagene zapreleucel (azer-cel)

    TG THERAPEUTICS, INC.

    B-cell Mediated Autoimmune Disorders

    phase 1 small molecule active

    1 trial

  24. Cosibelimab

    TG THERAPEUTICS, INC.

    B-cell Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  25. DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis, Myasthenia Gravis

    phase 1 small molecule active

    1 trial

  26. NM1F Injection

    TG THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  27. TG-1701

    TG THERAPEUTICS, INC.

    Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  28. TG-1801

    TG THERAPEUTICS, INC.

    CLL

    phase 1 mab terminated

    1 trial

  29. TG-1801

    TG THERAPEUTICS, INC.

    B-Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  30. TGI-5

    TG THERAPEUTICS, INC.

    CRC (Colorectal Cancer)

    phase 1 small molecule active

    1 trial

  31. TGI-6 Injection

    TG THERAPEUTICS, INC.

    Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  32. TGR-1202

    TG THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  33. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 1 small molecule completed

    1 trial

  34. TGR-1202

    TG THERAPEUTICS, INC.

    Non-Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  35. TGR-1202 + Obinutuzumab + Chlorambucil

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  36. TGR-1202 + brentuximab vedotin

    TG THERAPEUTICS, INC.

    Hodgkin's Lymphoma

    phase 1 small molecule completed

    1 trial

  37. Ublituximab + TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  38. Ublituximab

    TG THERAPEUTICS, INC.

    Multiple Sclerosis

    approved mab active

    4 trials

  39. Ublituximab

    TG THERAPEUTICS, INC.

    Multiple Sclerosis (MS) - Relapsing-remitting

    small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does TG THERAPEUTICS have?

39 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.